A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma
- Interventions
- Registration Number
- NCT05201248
- Lead Sponsor
- Genmab
- Brief Summary
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and toxicity of epcoritamab as a monotherapy and when combined with standard of care therapy \[Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or Rituximab and lenalidomide (R2)\] in adult participants in China with B-Cell Non-Hodgkin Lymphoma. Adverse events and change in disease activity will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of B-Cell Non-Hodgkin Lymphoma. Study doctors put the participants in groups called treatment arms. A monotherapy of epcoritamab and two different combination of epcoritamab with standard of care therapy (R-CHOP or R2) will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. Approximately 66 adult participants with B-Cell Non-Hodgkin Lymphoma will be enrolled in the study in approximately 21 sites in China.
In the monotherapy arm (Cohort 1), participants will receive subcutaneous epcoritamab in 28-day cycles. In the combination arms (Cohorts 2 and 3), participants in Cohort 2 will receive subcutaneous epcoritamab with standard of care therapy (R-CHOP) in 21-day cycles followed by 28-day cycles, participants in Cohort 3 will receive subcutaneous epcoritamab with standard of care therapy (R2) in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 49
All Cohorts:
-
Life expectancy of >= 3 months on standard of care (SOC).
-
Must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2.
-
Has one or more measurable disease sites:
- Fluorodeoxyglucose-positron emission tomography (FDGPET) scan demonstrating positive lesion compatible with computed tomography (CT) or magnetic resonance image (MRI)-defined anatomical tumor sites.
- >= 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or >= 1.0 measurable extra-nodal lesion (long axis >= 1 cm) on CT scan or MRI. Note: A previously irradiated lesion must have demonstrated progression or residual disease in the lesion after radiotherapy to be considered measurable.
Cohort 1 Part 1 (Monotherapy Safety Run-in) Specific Criteria:
- Must have histologically confirmed CD20+ Diffuse large B-cell lymphoma (DLBCL), or High-grade B-cell lymphoma (HGCBL) with MYC and BCL2 and/or BCL6 translocations and DLBCL feature, and follicular Lymphoma (FL) at most recent (previous or current) representative tumor biopsy based on the pathology report, according to the World Health Organization (WHO) 2016 (or later) classification.
- Must have at least one prior treatment with an anti-CD20 monoclonal antibody (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
- Must have relapsed or refractory disease. Note: Relapsed disease is defined as disease that has recurred >= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed or failed to achieve an objective response during therapy or progressed within 6 months (<6 months) of completion of therapy.
Cohort 1 Part 2 (Monotherapy Expansion) Specific Criteria:
-
Must have histologically confirmed CD20+ DLBCL at most recent (previous or current) representative tumor biopsy based on the pathology report, inclusive of the following according to the World Health Organization (WHO) 2016 (or later) classification.
- DLBCL, not otherwise specified (NOS) including de novo or histologically transformed from an earlier diagnosis of indolent lymphoma such as FL and nodal marginal zone lymphoma with a subsequent development of DLBCL relapse or.
- "Double-hit" or "triple-hit" with DLBCL morphology (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations). Note: Double- /triple-hit lymphomas without DLBCL morphology and those classified in WHO 2016 as HGBCL, NOS are not eligible.
- FL Grade 3B.
-
Following safety run-in and up to the 12th participant (including the number of safety run-in participants) in Cohort 1, participants must have received at least 1 prior line of systemic therapies which must include an anti-CD20 monoclonal antibody containing combination therapy (e.g., rituximab). After safety run-in confirms tolerability of the full dose A of epcoritamab, participants must have received at least 2 prior lines of systemic therapies.
-
Must have either failed prior autologous HSCT, or be ineligible for autologous HSCT due to age, comorbidities, performance status, comorbidities, or insufficient response to prior treatment.
-
Must have relapsed or refractory disease. Note: Relapsed disease is defined as disease that has recurred >= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed or failed to achieve an objective response during therapy or progressed within 6 months (< 6 months) of completion of therapy.
Cohort 2 Specific Criteria:
-
Must have newly diagnosed CD20+ DLBCL.
-
Must have one of the following histologically confirmed CD20+ DLBCL (de novo or histologically transformed from FL at most recent (previous or current) representative tumor biopsy based on the pathology report including one of the following diagnoses according to the WHO 2016 (or later) classification:
- DLBCL, not otherwise specified (NOS);
- "Double-hit" or "triple-hit" with DLBCL morphology (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations) Note: Double-/triple-hit lymphomas without DLBCL morphology and those classified in WHO 2016 as HGBCL, NOS are not eligible or;
- FL Grade 3B
-
Eligible for standard R-CHOP for 6 cycles.
Cohort 3 Specific Criteria:
- Must have histologically confirmed CD20+ Grade 1 - 3a Follicular Lymphoma stage II, III, or IV with no evidence of histologic transformation to an aggressive lymphoma at most recent (previous or current) representative tumor biopsy and based on the pathology report, according to the WHO 2016 (or later) classification.
- Must have R/R disease to at least one prior systemic anti-lymphoma treatment which must include an anti CD20 monoclonal antibody (e.g., rituximab). Participant who received only prior anti-CD20 monoclonal antibody monotherapy is not eligible. Note: Relapsed disease is defined as disease that previously responded to therapy but progressed >= 6 months after completion of therapy. Refractory disease is defined as disease that either progressed during therapy, failed to achieve an objective response or progressed within 6 months (< 6 months) of completion of therapy.
- Must be eligible for R2 per investigator determination.
- Willing to take aspirin prophylaxis (participants with low or intermediate risk for thromboembolism) or prophylactic anticoagulant (if high risk for a thromboembolic event) (lenalidomide treated participants only).
All Cohorts:
- History of primary mediastinal lymphoma.
- Autologous Stem Cell Transplantation within 100 days prior to enrollment.
- Have received prior allogeneic hematopoietic stem cell transplantation at any time.
- Have been treated with a bispecific antibody targeting CD3 and CD20.
Cohort 2 Specific Criteria:
- History of prior systemic anti-lymphoma therapy (including definitive radiotherapy) for Diffuse large B-cell lymphoma (DLBCL) other than corticosteroids.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 1 Part 2: Epcoritamab Expansion Epcoritamab Participants will receive SC epcoritamab in 28 day cycles. Cohort 1 Part 1: Epcoritamab Monotherapy Epcoritamab Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles. Cohort 3: Epcoritamab + R2 Rituximab Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, and oral lenalidomide (R2)\] in 28 day cycles. Cohort 2: Epcoritamab + RCHOP Cyclophosphamide Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 2: Epcoritamab + RCHOP Epcoritamab Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 2: Epcoritamab + RCHOP Rituximab Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 2: Epcoritamab + RCHOP Doxorubicin Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 2: Epcoritamab + RCHOP Vincristine Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 2: Epcoritamab + RCHOP Prednisone Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)\] in 21 day cycles followed by 28 day cycles. Cohort 3: Epcoritamab + R2 Epcoritamab Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, and oral lenalidomide (R2)\] in 28 day cycles. Cohort 3: Epcoritamab + R2 Lenalidomide Participants will receive SC epcoritamab in combination with \[intravenously (IV) infused rituximab, and oral lenalidomide (R2)\] in 28 day cycles.
- Primary Outcome Measures
Name Time Method Cohort 1 Part 2 [(3L+) R/R DLBCL]: Best Overall Response (BOR) Up to Approximately 5 Years Best overall response (BOR) is defined as the percentage of participants in Cohort 1 Part 2 third line plus (3L) R/R DLBCL who achieved best overall response of complete response (CR) or partial response (PR) by Lugano 2014 criteria as assessed by independent review committee (IRC).
Cohort 1 Part 1, Cohort 2, and Cohort 3: Number of Incidence of Dose-Limiting Toxicities (DLT) Up to Approximately 5 Years DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
- Secondary Outcome Measures
Name Time Method Cohort 1 Part 2 [(3L+) R/R DLBCL]: Time-to-response (TTR) Up to Approximately 5 Years TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by IRC.
Cohort 1 Part 2 [(3L+) R/R DLBCL]: Percentage of Participants with Complete Remission (CR) Up to Approximately 5 Years CR is defined as the absence of lymphoma determined by Lugano 2014 criteria as assessed by IRC.
Cohort 1 Part 2 [(3L+) R/R DLBCL]: Number of Participants with Progression-free survival (PFS) Up to Approximately 5 Years PFS is defined as the time in months from the first dose of study drug to the earliest occurrence of radiographic progression determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Cohort 1 Part 2 [(3L+) R/R DLBCL]: Overall survival (OS) Up to Approximately 5 Years OS is defined for Cohort 1 epcoritamab monotherapy participants, as the time in months from first dose of epcoritamab to death from any cause.
Cohort 1 Part 2 [(3L+) R/R DLBCL]: Duration of response (DOR) Up to Approximately 5 Years DOR is defined for participants who achieved best overall response of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of radiographic progression determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (18)
Tianjin Cancer Hospital /ID# 228135
🇨🇳Tianjin, Tianjin, China
Peking University Third Hospital /ID# 228138
🇨🇳Beijing, Beijing, China
The Fifth Medical Center of PLA General Hospital /ID# 230520
🇨🇳Beijing, Beijing, China
Henan Cancer Hospital /ID# 228772
🇨🇳Zhengzhou, Henan, China
Nanfang Hospital of Southern Medical University /ID# 227916
🇨🇳Guangzhou, Guangdong, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221
🇨🇳Wuhan, Hubei, China
Fujian Medical University Union Hospital /ID# 231890
🇨🇳Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center /ID# 228033
🇨🇳Guangzhou, Guangdong, China
Hunan Cancer Hospital /ID# 231859
🇨🇳Changsha, Hunan, China
The First Affiliated Hospital of Soochow University /ID# 228024
🇨🇳Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College /ID# 228774
🇨🇳Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University /ID# 228771
🇨🇳Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital /ID# 231944
🇨🇳Nanchang, Jiangxi, China
West China Hospital, Sichuan University /ID# 231434
🇨🇳Chengdu, Sichuan, China
Guangdong Provincial People's Hospital /ID# 228028
🇨🇳Guangzhou, Guangdong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 228154
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer hospital /ID# 228776
🇨🇳Hangzhou, Zhejiang, China